SCM
STIM icon

Sterling Capital Management’s Neuronetics STIM Stock Holding History

Sterling Capital Management’s Portfolio STIM Stock Details STIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-235
Closed -$341 – 3410
2026
Q1 		$341 Hold
235
– – ﹤0.01% 3180
2025
Q4 		$324 Buy
235
+147
+167% +$308 ﹤0.01% 3213
2025
Q3 		$240 Buy
88
+1
+1% +$4 ﹤0.01% 3205
2025
Q2 		$304 Buy
+87
New +$343 ﹤0.01% 3203

Other funds holding STIM

MAM
Madryn Asset Management New York $36.9M AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
FCM
FourWorld Capital Management New York $110M AUM 44.07% 1-Year Est. Return
LG
Lane Generational Dover, Massachusetts $114M AUM 43.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sterling Capital Management's STIM Position: Q2 2026 in Review

Sterling Capital Management sold out of Neuronetics (STIM) in Q2 2026, closing a stake of 235 shares — an estimated $341 sold.

Sterling Capital Management first reported a position in STIM in Q2 2025 and held it in 4 quarters. The position peaked at $341 in Q1 2026. 86 funds tracked by Wall St. Rank hold STIM as of Q2 2026.

  • Sterling Capital Management reported no remaining Neuronetics position as of Q2 2026 after selling out during the quarter.
  • Sterling Capital Management sold 235 Neuronetics shares in Q2 2026, an estimated $341.
  • Sterling Capital Management first reported a position in Neuronetics in Q2 2025 and held it in 4 quarters.
  • Sterling Capital Management's Neuronetics position peaked at $341 in Q1 2026.
  • 86 funds tracked by Wall St. Rank held Neuronetics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.